Biomarkers for Dementia
1Department of Biological Regulation, Faculty of Medicine, Tottori University, Yonago, Tottori 680-8550, Japan
2Department of Geriatrics and Gerontology, Division of Brain Science, Institute of Development, Aging and Cancer, Tohoku University, Sendai 980-8575, Japan
3Transitional Medicine, Pfizer Global Research and Development Eastern Pt, Road, Groton, CT 06340, USA
4Laboratorio di Epidemiologia, Neuroimaging e Telemedicina, IRCCS Centro San Giovanni di Dio FBF, Via Pilastroni 1, Brescia, Italy
Biomarkers for Dementia
Description
The development of treatments for dementia is advancing with steady steps, and early diagnosis is considered critical. Biomarkers are central components of drug development in Alzheimer's disease and related disorders including dementia with lewy bodies, frontotemporal dementia, and vascular dementia, and so forth. Therefore, we would like to focus upon biomarkers as the theme.
We invite authors to submit original research and review articles about biomarkers for Alzheimer's disease and related disorders including dementia with lewy bodies, frontotemporal dementia, and vascular dementia in basic and clinical research. Potential topics include, but are not limited to:
- Recent developments of genetic testing
- Advances of structural imaging (CT, MRI, etc.)
- Advances of functional imaging (SPECT, PET, Amyloid imaging, etc.)
- Recent developments of peripheral markers (cerebrospinal fluid, serum, fibroblast, etc.)
- Role of new biomarkers for disease modifying therapies
Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ijad/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: